| NCT Number | NCT06868264 |
| Lead Sponsor | Atea Pharmaceuticals, Inc. |
| Conditions | HEPATITIS C VIRUS CHRONIC INFECTION |
| Enrollment | 880 participants |
| Start Date | 2025-04-07 |
| Primary Completion | 2026-09 (estimated) |
| Study Completion | 2026-12 (estimated) |
| Updated on ClinicalTrials.gov | 2025-12-05 |